A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

January 31, 2018

Study Completion Date

August 30, 2018

Conditions
Mucocutaneous Lymph Node SyndromeKawasaki Disease
Interventions
DRUG

Etanercept

etanercept 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.

DRUG

Placebo

Placebo 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.

Trial Locations (8)

10032

Columbia University Medical Center, New York

10467

Montefiore Medical Center, The Bronx

11040

Feinstein Institute for Medical Rsearch, New Hyde Park

53201

Children's Hospital of Wisconsin, Milwaukee

77030

Texas Children's Hospital, Houston

84113

Primary Children's Medical Center, Salt Lake City

98105

Seattle Children's Hospital, Seattle

H3T 1C5

Sainte-Justine Hospital, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Michael Portman

OTHER

NCT00841789 - A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease | Biotech Hunter | Biotech Hunter